IP Library Granted Patent US 10,995,135
Granted Patent B2
US 10,995,135 · App. 16/681,926 · Granted May 4, 2021

Patent

Inventor: Kenji Saito (Izunokuni, JP)
Assignee: TAUNS CO., LTD.
C07K16/1253G01N33/558G01N33/56933G01N2333/30G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,995,135
App. No.
16/681,926
Granted
May 4, 2021
Kind
B2
Abstract

[Problem] An object of the present invention is to provide a detection marker that can simply and rapidly detect Mycoplasma pneumoniae , which is a pathogen of mycoplasma pneumonia, at a high sensitivity, a specific antibody against the marker, and also an immunological detection method and a kit containing the antibody. [Solution] Infection with Mycoplasma pneumoniae can be rapidly and specifically diagnosed by producing an antibody specifically reactive to P30 protein of Mycoplasma pneumoniae and performing an immunological assay using the P30 protein as a detection marker. The present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the bacteria at a hospital or the like without need of specialized instruments or skilled techniques.

Claims (6)

1. A monoclonal antibody that specifically binds an epitope of P30 protein of Mycoplasma pneumoniae , said epitope being present in a region of the amino acid sequence of SEQ ID NO: 2, which has a sensitivity sufficient for detecting Mycoplasma pneumoniae strain M129 in a culture having a concentration of 1×10 6 CFU/mL of the M129 strain, as measured by an immunochromatographic assay for detecting Mycoplasma pneumoniae , comprising:

providing a membrane carrier having a capturing zone that is formed by previously immobilizing the monoclonal antibody as a first antibody against the P30 protein at a predetermined position;

chromatographically developing a liquid mixture in the membrane carrier toward the capturing zone, said liquid mixture containing the monoclonal antibody as a second antibody against the P30 protein and the aforementioned culture,

whereby a complex of an antigen contained in the culture and the second antibody is captured by the capturing zone.

2. The monoclonal antibody according to claim 1 , which has a sensitivity sufficient for detecting Mycoplasma pneumoniae strain FH in a culture having a concentration of 1×10 6 CFU/mL of the HI strain, as measured above.

3. The monoclonal antibody according to claim 1 , which is at least essentially free from cross-reactivity with Mycoplasma genitalium.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: SAITO, KENJI
To: BL CO., LTD.
Reel/Frame 050990/0280 →
MERGER Recorded Nov 13, 2019
From: BL CO., LTD.
To: ARNO CO., LTD.
Reel/Frame 050990/0463 →
MERGER Recorded Nov 13, 2019
From: ARNO CO., LTD.
To: TAUNS CO., LTD.
Reel/Frame 050990/0709 →
Priority Claims (1)
JP 2013-173991 · Aug 23, 2013 · national
Continuity (3)
Division 16193909 · Nov 16, 2018
Division 14913612
Related Publication 20200079839A1 · Mar 12, 2020